Antiviral activity of lanatoside C against dengue virus infection

Dengue Infection poses a serious threat globally due to its recent rapid spread and rise in incidence. Currently, there is no approved vaccine or effective Antiviral drug for Dengue virus infection. In response to the urgent need for the development of an effective Antiviral for Dengue virus, the US Drug Collection library was screened in this study to identify compounds with anti-dengue activities. Lanatoside C, an FDA approved cardiac glycoside was identified as a candidate anti-dengue compound. Our data revealed that lanatoside C has an IC50 of 0.19μM for Dengue virus infection in HuH-7 cells. Dose-dependent reduction in dengue viral RNA and Viral Proteins synthesis were also observed upon treatment with increasing concentrations of lanatoside C. Time of addition study indicated that lanatoside C inhibits the early processes of the Dengue virus replication cycle. Furthermore, lanatoside C can effectively inhibit all four serotypes of Dengue virus, Flavivirus Kunjin, alphavirus Chikungunya and Sindbis virus as well as the human Enterovirus 71. These findings suggest that lanatoside C possesses broad spectrum Antiviral activity against several groups of positive-sense RNA viruses.